Accessibility Menu
Arrow-Thin-Down
S&P 500
6,830.71
-0.6%
-38.79
Arrow-Thin-Down
DJI
47,954.74
-1.6%
-784.67
Arrow-Thin-Down
NASDAQ
22,748.99
-0.3%
-58.50
Arrow-Thin-Down
Bitcoin
$71,003.00
-1.4%
-$1,041.65
Arrow-Thin-Down
AMZN
$218.93
+1.0%
+$2.11
Arrow-Thin-Down
GOOG
$300.91
-0.8%
-$2.54
Arrow-Thin-Down
META
$660.65
-1.1%
-$7.08
Arrow-Thin-Down
MSFT
$410.89
+1.4%
+$5.69
Arrow-Thin-Down
NVDA
$183.23
+0.1%
+$0.19
Arrow-Thin-Down
TSLA
$405.55
-0.1%
-$0.39
Most Active StocksDaily Stock GainersDaily Stock Losers
Cytokinetics Stock Quote

Cytokinetics (NASDAQ: CYTK)

$62.24
(-0.0%)
-0.03
Price as of March 5, 2026, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$62.24
Daily Change
(-0.0%) $0.03
Day's Range
$60.84 - $62.45
Previous Close
$62.24
Open
$61.77
Beta
0.99
Volume
47,806
Average Volume
1,928,968
Sector
Health Care
Market Cap
$7.7B
Market Cap / Employee
$62.19M
52wk Range
$29.31 - $70.98
Revenue
N/A
Gross Margin
0.88%
Dividend Yield
N/A
EPS
-$6.53
CAPs Rating
N/A
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Cytokinetics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CYTK+41.73%+216.01%+25.86%-36%
S&P+16.91%+77.79%+12.19%+513%

Cytokinetics Company Info

Cytokinetics is a biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of cardiovascular diseases and cancer.

News & Analysis

Featured Article

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

B. Lynne Parshall sold $323,650 worth of Cytokinetics shares in November.

Sarah Sidlow  |  Dec 19, 2025
Featured Article

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Cory Renauer  |  Dec 8, 2025

Financial Health

General

Q4 2025YOY Change
Revenue$17.76M4.9%
Gross Profit$14.89M2.4%
Gross Margin83.89%-2.0%
Market Cap$7.77B39.9%
Market Cap / Employee$11.54M0.0%
Employees67335.1%
Net Income-$183,031.00K-22.0%
EBITDA-$175,505.00K-28.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q4 2025YOY Change
Net Cash$125.63M31.9%
Accounts Receivable$17.76M6.7%
Inventory00.0%

Liabilities

Q4 2025YOY Change
Long Term Debt$1.22B61.4%
Short Term Debt$60.29M97.7%

Ratios

Q4 2025YOY Change
Return On Assets-55.55%-2.6%
Return On Invested Capital-80.98%1.3%

Cash Flow

Q4 2025YOY Change
Free Cash Flow-$148,295.00K-121.8%
Operating Free Cash Flow-$142,651.00K-117.6%

Valuation

MetricQ1 2025Q2 2025Q3 2025Q4 2025YoY Change
Price to Book-35.09-14.79-17.83-14.89-96.26%
Price to Sales247.8146.0375.6188.36-70.61%
Price to Tangible Book Value-35.09-14.79-17.83-14.89-96.26%
Enterprise Value to EBITDA-30.10-36.12-41.60-46.6020.92%
Total Debt$791.06M$858.06M$1.20B$1.28B62.84%

No results found

No podcast episodes available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services